

SOPHiA EXTENDED CARDIO SOLUTION™

The genomic application that bundles a capture-based target enrichment kit with the analytical power of SOPHiA™ AI and full access to the SOPHiA DDM™ platform.



The ExtCAS application covers the coding regions and splicing junctions (\pm 5bp) of 128 most relevant genes (target region of 470 kb), associated with arrhythmias (e.g. Long/Short QT syndrome or Brugada syndrome) and cardiomyopathies. Probe design is optimized to guarantee high on-target rate and coverage uniformity even in GC-rich regions, including the first exon.

Gene panel

128 genes

For more information on the covered genes, visit:
<https://www.sophiagenetics.com/cardiosolutions>

Recommendations

Starting material: 200 ng

Sample source: Blood

Samples per run: Depending on sequencing platform⁽¹⁾

Sequencer	Flow Cell / Ion Chip Kit	Recommended samples per run (for 250x median coverage depth)
Illumina MiSeq®	v3 (2x300bp)	12
Illumina NextSeq® 500/550	Mid Output Kit (2x150bp)	48
Ion S5™	Ion 540	16

Wet lab

Day 1: Library Preparation

Day 2: Capture and Sequencing

Library preparation time: 8 hours

SOPHiA analyzes complex NGS data by detecting, annotating and pre-classifying genomic variants to support experts on data-informed decision making. It enables accurate and comprehensive detection of SNVs, Indels and CNVs⁽²⁾ in all genes of the panel.

SOPHiA reaches advanced analytical performance:

	Observed
Sensitivity	100%
Specificity	99.99%
Accuracy	99.99%
Precision	98.68%
Repeatability	99.99%
Reproducibility	99.98%
Average on-target rate	89.60%
Coverage uniformity	99.84%
Average % of target region with depth > 200x	99.96%

Analysis time from FASTQ files: 4 hours⁽³⁾

The results are presented in SOPHiA DDM, the platform of choice for experts performing genomic testing. Its intuitive user interface and advanced features facilitate the visualization and interpretation of genomic variants. Data is kept safe by applying the highest industrial standards of encryption.

Main features

Dedicated features in SOPHiA DDM reduce the complexity of determining the significance of genomic variants.

- **Dual variant pre-classification:** Improve assessment of variants pathogenicity with the pre-classification of both ACMG guidelines and SOPHiA's prediction
- **Virtual Panels:** Restrict the interpretation to sub-panels of genes (e.g. focus on arrhythmias or cardiomyopathies)
- **Variant Filter Builder:** Define and edit custom filters for efficient analysis

Access to SOPHiA's Community

In SOPHiA DDM, experts from hundreds of healthcare institutions interpret the results and flag the pathogenicity level of variants according to their knowledge and experience. This highly valuable information feeds the variant knowledge base and is anonymously and safely shared among the members of the community.

All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them

(1) Sequencing recommendations and specifications for other sequencing kits and instruments available upon request. Delivery time may vary according to the selected sequencing platform

(2) CNV detection not available for exon 47 of *FLNC* and exons 172-197 of *TTN*

(3) Analysis time may vary depending on the number of samples multiplexed and server load